Patients' results
| Patient no. . | Sex . | Age, y . | Donor . | Lille score at SCT . | Myelofibrosis . | Acute GVHD, grade . | Chronic GVHD . | Negativity of JAK2 after allo, d . | Follow-up, mo . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 46 | Rel | Intermediate | Primary | 2 | Lim | 48 | 28+ alive, JAK2 neg |
| 2 | M | 51 | MUD | Low | Primary | 0 | Lim | Never | 40+ alive, JAK2 pos |
| 3 | M | 56 | MUD | Intermediate | Primary | 0 | 0 | 102 | 4+ alive, JAK2 neg |
| 4 | M | 48 | MUD | Intermediate | Primary | 1 | 0 | 42 | 18+ alive, JAK2 neg |
| 5 | M | 32 | MUD | High | Primary | 3 | Extensive | 89 | 33+ alive, JAK2 neg |
| 6 | F | 63 | MUD | Intermediate | Secondary (PV) | 0 | 0 | Never | 13+ alive, JAK2 pos |
| 7 | M | 53 | MUD | sAML | Primary | 0 | 0 | 55 | 8, relapse (AML)* |
| 8 | M | 63 | MUD | Intermediate | Primary | 0 | Lim | 94 | 26+ alive, JAK2 neg |
| 9 | F | 52 | MUD | sAML | Primary | 0 | 0 | 176 | 23+ alive, JAK2 neg |
| 10 | M | 55 | MUD | High | Primary | 1 | 0 | Never | 4, dead, TRM, JAK2 pos* |
| 11 | M | 46 | MUD | Intermediate | Primary | 0 | Extensive | 160 | 19+ alive, JAK2 neg |
| 12 | M | 55 | MUD | Intermediate | Primary | 0 | Extensive | 29 | 20+ alive, JAK2 neg |
| 13 | F | 48 | MUD | Low | Secondary (PV) | 0 | 0 | 37 | 3+ alive, JAK2 neg |
| 14 | M | 49 | MUD | Intermediate | Secondary (PV) | 0 | Lim | Never | 20+ alive, JAK2 pos |
| 15 | M | 51 | Rel | Intermediate | Secondary (PV) | 0 | Lim | 65 | 51+ alive, JAK2 neg |
| 16 | M | 54 | MUD | Low | Primary | 2 | 0 | 147 | 18+ alive, JAK2 neg |
| 17 | M | 58 | Rel | Intermediate | Primary | 1 | Lim | 38 | 27+ alive, JAK2 neg |
| 18 | F | 47 | Rel | Low | Primary | 2 | Extensive | Unknown | 38+ alive, JAK2 neg |
| 19a† | M | 60 | MUD | Intermediate | Secondary (ET) | 0 | 0 | Never | 16+ alive |
| 19b† | M | 61 | MUD | Intermediate | Secondary (ET) | 3 | Lim | 118 | 5+ alive, JAK2 neg |
| 20 | M | 53 | Rel | Intermediate | Secondary (PV) | 2 | Lim | 750 (after DLI) | 40+ alive, JAK2 pos |
| 21 | M | 46 | MUD | Intermediate | Primary | 0 | 0 | 19 | 3+ alive, JAK2 neg |
| Patient no. . | Sex . | Age, y . | Donor . | Lille score at SCT . | Myelofibrosis . | Acute GVHD, grade . | Chronic GVHD . | Negativity of JAK2 after allo, d . | Follow-up, mo . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 46 | Rel | Intermediate | Primary | 2 | Lim | 48 | 28+ alive, JAK2 neg |
| 2 | M | 51 | MUD | Low | Primary | 0 | Lim | Never | 40+ alive, JAK2 pos |
| 3 | M | 56 | MUD | Intermediate | Primary | 0 | 0 | 102 | 4+ alive, JAK2 neg |
| 4 | M | 48 | MUD | Intermediate | Primary | 1 | 0 | 42 | 18+ alive, JAK2 neg |
| 5 | M | 32 | MUD | High | Primary | 3 | Extensive | 89 | 33+ alive, JAK2 neg |
| 6 | F | 63 | MUD | Intermediate | Secondary (PV) | 0 | 0 | Never | 13+ alive, JAK2 pos |
| 7 | M | 53 | MUD | sAML | Primary | 0 | 0 | 55 | 8, relapse (AML)* |
| 8 | M | 63 | MUD | Intermediate | Primary | 0 | Lim | 94 | 26+ alive, JAK2 neg |
| 9 | F | 52 | MUD | sAML | Primary | 0 | 0 | 176 | 23+ alive, JAK2 neg |
| 10 | M | 55 | MUD | High | Primary | 1 | 0 | Never | 4, dead, TRM, JAK2 pos* |
| 11 | M | 46 | MUD | Intermediate | Primary | 0 | Extensive | 160 | 19+ alive, JAK2 neg |
| 12 | M | 55 | MUD | Intermediate | Primary | 0 | Extensive | 29 | 20+ alive, JAK2 neg |
| 13 | F | 48 | MUD | Low | Secondary (PV) | 0 | 0 | 37 | 3+ alive, JAK2 neg |
| 14 | M | 49 | MUD | Intermediate | Secondary (PV) | 0 | Lim | Never | 20+ alive, JAK2 pos |
| 15 | M | 51 | Rel | Intermediate | Secondary (PV) | 0 | Lim | 65 | 51+ alive, JAK2 neg |
| 16 | M | 54 | MUD | Low | Primary | 2 | 0 | 147 | 18+ alive, JAK2 neg |
| 17 | M | 58 | Rel | Intermediate | Primary | 1 | Lim | 38 | 27+ alive, JAK2 neg |
| 18 | F | 47 | Rel | Low | Primary | 2 | Extensive | Unknown | 38+ alive, JAK2 neg |
| 19a† | M | 60 | MUD | Intermediate | Secondary (ET) | 0 | 0 | Never | 16+ alive |
| 19b† | M | 61 | MUD | Intermediate | Secondary (ET) | 3 | Lim | 118 | 5+ alive, JAK2 neg |
| 20 | M | 53 | Rel | Intermediate | Secondary (PV) | 2 | Lim | 750 (after DLI) | 40+ alive, JAK2 pos |
| 21 | M | 46 | MUD | Intermediate | Primary | 0 | 0 | 19 | 3+ alive, JAK2 neg |
Unknown indicates that no sample immediately after allo-SCT was available.
The patient died.
GVHD indicates graft-versus-host disease; Rel, HLA-identical sibling; Lim, limited; MUD, matched unrelated donor; PV, polycythemia vera; sAML, secondary acute myeloid leukemia; TRM, transplant-related mortality; ET, essential thrombocythemia; SCT, stem cell transplantation; DLI, donor lymphocyte infusion.
Same patient; two different SCTs.